AR119839A1 - Eritropoyetina humana recombinante hiposialilada para el tratamiento de alteraciones del sistema nervioso - Google Patents

Eritropoyetina humana recombinante hiposialilada para el tratamiento de alteraciones del sistema nervioso

Info

Publication number
AR119839A1
AR119839A1 ARP200102407A ARP200102407A AR119839A1 AR 119839 A1 AR119839 A1 AR 119839A1 AR P200102407 A ARP200102407 A AR P200102407A AR P200102407 A ARP200102407 A AR P200102407A AR 119839 A1 AR119839 A1 AR 119839A1
Authority
AR
Argentina
Prior art keywords
recombinant human
human erythropoietin
nervous system
pharmaceutical composition
hyposialylated
Prior art date
Application number
ARP200102407A
Other languages
English (en)
Inventor
Obaya Teresita De Jesus Rodrguez
Gonzlez Daniel Enrique Amaro
Artalejo Judey Aymed Garca
Test Iliana Maria Sosa
Conde Yanara Sarmiento
De La Rosa Lourdes Hernndez
Goire Dayli Daz
Original Assignee
Ct Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Inmunologia Molecular filed Critical Ct Inmunologia Molecular
Publication of AR119839A1 publication Critical patent/AR119839A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente se relaciona con las ramas de la biotecnología y la medicina y describe una composición farmacéutica de eritropoyetina humana recombinante con la microheterogeneidad de N-glicanos fucosilados formada por estructuras bi, tri y tetra-antenarias con residuos de ácidos siálicos mono y bi-sialilados que se encuentran en un rango del 40 - 60% del total de glicanos, los trisialilados entre un 40 - 43% y los tretrasialilados entre 10 - 13%, este patrón de glicosilación le confiere propiedades que permiten su uso en alteraciones del sistema nervioso. Se describe además el método de obtención de la composición farmacéutica aquí descrita. Reivindicación 1: Una composición farmacéutica caracterizada porque comprende como principio activo una eritropoyetina humana recombinante (EPOhr) con un perfil de punto isoeléctrico comprendido entre 4,25 y 5,85.
ARP200102407A 2019-09-05 2020-08-26 Eritropoyetina humana recombinante hiposialilada para el tratamiento de alteraciones del sistema nervioso AR119839A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2019000077A CU24704B1 (es) 2019-09-05 2019-09-05 Método para la obtención de eritropoyetina humana recombinante hiposialilada para el tratamiento de alteraciones del sistema nervioso

Publications (1)

Publication Number Publication Date
AR119839A1 true AR119839A1 (es) 2022-01-12

Family

ID=72242895

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200102407A AR119839A1 (es) 2019-09-05 2020-08-26 Eritropoyetina humana recombinante hiposialilada para el tratamiento de alteraciones del sistema nervioso

Country Status (15)

Country Link
US (1) US20220305084A1 (es)
EP (1) EP4026555A1 (es)
JP (1) JP2022546837A (es)
KR (1) KR20220057553A (es)
CN (1) CN114340653B (es)
AR (1) AR119839A1 (es)
AU (1) AU2020342140B2 (es)
BR (1) BR112022002954A2 (es)
CA (1) CA3150952A1 (es)
CO (1) CO2022002934A2 (es)
CU (1) CU24704B1 (es)
MX (1) MX2022002765A (es)
TW (1) TW202114729A (es)
WO (1) WO2021043345A1 (es)
ZA (1) ZA202203661B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024094457A1 (en) * 2022-11-02 2024-05-10 F. Hoffmann-La Roche Ag Method for producing glycoprotein compositions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100263845B1 (ko) * 1989-10-13 2000-08-16 스튜어트 엘.왓트 에리트로포이에틴 동형체와 그의 제조방법 및 그를 포함하는제약학적 조성물
US7078376B1 (en) * 2000-08-11 2006-07-18 Baxter Healthcare S.A. Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
EP1552298A4 (en) * 2002-07-01 2006-11-08 Kenneth S Warren Inst Inc RECOMBINANT TISSUE-PROOFING CYTOKINS AND NUCLEIC ACIDS COORDINATING THEREOF FOR THE PROTECTION, RECOVERY AND IMPROVEMENT OF CELLS, TISSUE AND ORGANS THEREOF
EP1699821B1 (en) * 2003-12-31 2012-06-20 Merck Patent GmbH Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
CN101090973B (zh) * 2004-12-30 2012-03-28 克鲁塞尔荷兰公司 从表达腺病毒e1a蛋白的细胞中获得唾液酸化增加的重组蛋白质的方法及由此获得的蛋白质
CU23317A1 (es) * 2005-07-22 2008-10-22 Ct De Investigacia N Y Desarro Formulaciones nasales de eporh con bajo contenido de ã cido siã lico para el tratamiento de enfermedades del sistema nervioso central
CN101448852A (zh) * 2005-12-20 2009-06-03 布里斯托尔—迈尔斯斯奎布公司 组合物和用于生产组合物的方法
BRPI0711898A2 (pt) * 2006-05-19 2011-12-27 Glycofi Inc composiÇço de proteÍna da eritropoietina substancialmente homogÊnea, composiÇço farmacÊutica, e, mÉtodos de aumentar hematàcrito em um mamÍfero, e de produzir uma composiÇço de eritropoietina
KR101847169B1 (ko) * 2015-10-07 2018-04-09 주식회사 녹십자 지속형 에리트로포이에틴 함유 조성물
CA3065540A1 (en) * 2017-06-06 2018-12-13 Kindred Biosciences, Inc. Erythropoietin and analogs for veterinary use

Also Published As

Publication number Publication date
KR20220057553A (ko) 2022-05-09
CN114340653A (zh) 2022-04-12
CN114340653B (zh) 2023-01-31
CU20190077A7 (es) 2021-04-07
CO2022002934A2 (es) 2022-04-19
BR112022002954A2 (pt) 2022-05-17
CU24704B1 (es) 2024-04-08
EP4026555A1 (en) 2022-07-13
JP2022546837A (ja) 2022-11-09
TW202114729A (zh) 2021-04-16
ZA202203661B (en) 2023-09-27
MX2022002765A (es) 2022-04-06
CA3150952A1 (en) 2021-03-11
AU2020342140B2 (en) 2024-05-02
US20220305084A1 (en) 2022-09-29
AU2020342140A1 (en) 2022-04-07
WO2021043345A1 (es) 2021-03-11

Similar Documents

Publication Publication Date Title
CU20190073A7 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas
CR20170492A (es) Composiciones de ácido obeticólico y métodos de uso.
CL2018001089A1 (es) Sales de valbenazina y polimorfos de las mismas.
CR20180185A (es) Métodos y composiciones para el tratamiento de estados de enfermedad asociados con respuestas inflamatorias anormales
GT201700184A (es) Nuevas proteínas específicas para pioverdina y pioquelina
BR112018010158A2 (pt) roedor, polipeptídeo lag-3 humanizado, célula ou tecido, célula-tronco embrionária e embrião de roedor, métodos para produzir um roedor, para avaliar a eficácia antitumoral e as propriedades farmacocinéticas de uma droga
BR112019006113A2 (pt) métodos de tratamento de distúrbios mitocondriais e metabólicos
BR112017015310A2 (pt) uso de pgr4 como um agente anti-inflamatório
CL2015003346A1 (es) Composiciones de cenicriviroc y métodos para realizarlas y utilizarlas
ECSP17046848A (es) Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desórdenes inflamatorios y osteoartritis
BR112018067946A2 (pt) formulações tópicas contendo ciclosporina e usos das mesmas
BR112018072034A2 (pt) compostos mic-1 e usos dos mesmos
CL2020001495A1 (es) Composiciones y método para el tratamiento de enfermedades metabólicas
CO2019011546A2 (es) Compuestos y métodos para el tratamiento de enfermedades parasitarias
BR112017007428A2 (pt) composições de éster de ácido graxo e ácidos graxos autocomnizantes e suas utilizações no tratamento de estados da doença
AR119839A1 (es) Eritropoyetina humana recombinante hiposialilada para el tratamiento de alteraciones del sistema nervioso
WO2016029136A8 (en) 3-amidobenzamides and uses thereof for increasing cellular levels of a3g
CO2021013171A2 (es) Compuestos y composiciones como moduladores de la señalización de tlr
WO2022183074A3 (en) Anti-psma antibodies and car-t structures
MX2023009882A (es) Anticuerpos anti-muc1-c y estructuras car-t.
BR112018006414A2 (pt) processo para produzir fosfinatos
BR112018014525A2 (pt) compostos que antagonizam receptor de adenosina a3, método para preparação dos mesmos e aplicação médica dos mesmos
CL2020001791A1 (es) Composiciones farmacéuticas para la piel tópicas que contienen cerdulatinib y usos de estas.
BR112019005426A2 (pt) composições de éster de colina de ácido lipoico e métodos para estabilizar em produtos de fármaco farmaceuticamente relevantes
WO2016191458A3 (en) Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment